Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1Breast 1

Conditions

Leukemia, Myeloid, Acute 93Leukemia, Lymphocytic, Chronic, B-Cell 56Neoplasms 37Recurrence 28Lymphoma, Non-Hodgkin 25Myelodysplastic Syndromes 21Multiple Myeloma 18Leukemia 16Lymphoma, Large B-Cell, Diffuse 11Leukemia, Myelomonocytic, Chronic 10Hematologic Neoplasms 10Lymphoma, Mantle-Cell 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Follicular 7Lymphoma, B-Cell, Marginal Zone 6Leukemia, Myeloid 6Lymphoma 5Chromosome 17 deletion 5Lymphoma, B-Cell 4Breast Neoplasms 4Waldenstrom Macroglobulinemia 3Small Cell Lung Carcinoma 3Carcinoma, Non-Small-Cell Lung 3Neuroblastoma 2Neoplasms, Plasma Cell 2Neoplasm Metastasis 2Myeloproliferative Disorders 2Lymphoproliferative Disorders 2Hematologic Diseases 2GATA2 Deficiency 2

Interventions

pembrolizumab 98Gemcitabine 70Paclitaxel 59Docetaxel 52Carboplatin 49Cisplatin 40Nivolumab 39Capecitabine 35Pemetrexed 33Fluorouracil 32Bevacizumab 32Cetuximab 31130-nm albumin-bound paclitaxel 28Trastuzumab 26Irinotecan 24Albumin-Bound Paclitaxel 24Fulvestrant 22Leucovorin 20Oxaliplatin 18Panitumumab 17abemaciclib 16Ipilimumab 16cemiplimab 14atezolizumab 14Letrozole 14Cyclophosphamide 14palbociclib 12Lapatinib 12Drug Therapy 12Doxorubicin 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasm Metastasis × venetoclax × Clear all
NCT04553692 2025-03-28

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

IGM Biosciences, Inc.

Phase 1 Terminated
272 enrolled
GastrointestinalLymphoidOther hematologic neoplasmSarcoma

Chondrosarcoma, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

NCT04274933 2020-10-29

A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy

AbbVie

Phase 1 Terminated
4 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡